Literature DB >> 12915632

Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.

Teiji Takeda1, Hidehumi Inaba, Masanori Yamazaki, Satoru Kyo, Takahide Miyamoto, Satoru Suzuki, Takashi Ehara, Tomoko Kakizawa, Masahiro Hara, Leslie J DeGroot, Kiyoshi Hashizume.   

Abstract

A tumor-specific targeting system for cancer gene therapy was studied using the human telomerase reverse transcriptase (hTERT) promoter. Telomerase activity is increased in most tumors but not detected in most normal cells. We developed the recombinant adenovirus, carrying human herpes simplex virus thymidine kinase gene under the control of the hTERT promoter (AdhTERTtk) to obtain restricted expression of a suicide gene only in tumor cells. We found that transcriptional activity of hTERT was 2- to 9-fold higher in undifferentiated thyroid carcinoma cell lines than that of the Simian virus 40 promoter in transient transfection assay. Undifferentiated thyroid carcinoma cell lines were infected with AdhTERTtk, and sensitivity to ganciclovir (GCV) was analyzed. Cell viability was decreased in a GCV dose-dependent manner after treatment with AdhTERTtk/GCV. The cell-killing ability of AdhTERTtk in all thyroid or nonthyroid carcinoma cell lines tested was similar to AdCMVtk, which carries herpes simplex virus thymidine kinase gene driven by the cytomegalovirus promoter. However, normal cell lines were largely unaffected by AdhTERTtk/GCV, whereas these cells were also sensitive to GCV after infection with AdCMVtk. A xenograft model was established by transplanting human differentiated or undifferentiated thyroid carcinoma cells into Balb-C nude mice. The injections of AdhTERTtk into tumors and ip administration of GCV showed significant inhibition of tumor growth, similar to AdCMVtk/GCV treatment. Systemic administrations of adenovirus and GCV to normal rats demonstrated remarkable increase of serum liver transaminase levels and severe hepatic damages in pathological examinations in AdCMVtk-injected rats but not in the AdhTERTtk group. These results indicate that the AdhTERTtk/GCV system is a promising therapy for undifferentiated thyroid carcinoma, which is one of the most malignant tumors, without damage to normal tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915632     DOI: 10.1210/jc.2002-021856

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

2.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

3.  Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer.

Authors:  Cong-Xiang Shen; Zhong Wen; Yu-Hong Qian; Shao-Feng Mu; Xiao-Fang Guan
Journal:  J Exp Clin Cancer Res       Date:  2010-07-13

4.  Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.

Authors:  Qi Sun; Xiaoli Wang; Chunying Cui; Jing Li; Yifan Wang
Journal:  Int J Nanomedicine       Date:  2018-06-27

5.  Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.

Authors:  Marilena Celano; Maria Grazia Calvagno; Stefania Bulotta; Donatella Paolino; Franco Arturi; Domenicoantonio Rotiroti; Sebastiano Filetti; Massimo Fresta; Diego Russo
Journal:  BMC Cancer       Date:  2004-09-13       Impact factor: 4.430

6.  Enhancement of nanoparticle-mediated double suicide gene expression driven by 'E9-hTERT promoter' switch in dedifferentiated thyroid cancer cells.

Authors:  Aoshuang Chang; Junjun Ling; Huiping Ye; Houyu Zhao; Xianlu Zhuo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.